Latest news with #SinoUniversalPharmaceuticals
The Hindu
16-06-2025
- Business
- The Hindu
Lupin, China's SUP ink pact for COPD drug Tiotropium DPI
Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese market. Under the partnership that will enable Lupin to expand footprint in China, SUP will obtain regulatory approvals for selling Tiotropium DPI in China. Lupin will be the marketing authorisation holder and responsible for manufacturing of the product. Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. Their partnership comes in backdrop of increasing prevalence of respiratory conditions, Lupin said in a release on Monday. 'This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector,' Lupin's President of Corporate Development Fabrice Egros said. SUP president Wang Li said 'by bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health.' Lupin shares closed with a gain of less than 1% on the BSE at ₹2,010.55 each on Monday.
Business Standard
16-06-2025
- Business
- Business Standard
Lupin inks licensing deal with Sino Universal pharma for Tiotropium DPI drug in China
Lupin announced that it has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI) capsules in China for the treatment of chronic obstructive pulmonary disease. As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing the product. Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. This partnership will enable Lupin to expand its footprint in China, ensuring that patients have timely access to innovative and high-quality healthcare solutions, considering the increasing prevalence of respiratory conditions. Fabrice Egros, president of corporate development, Lupin, said, "We are very pleased to partner with SUP to bring Tiotropium DPI to patients in China. This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector. SUP is our esteemed partner in this endeavor, and together we aim to enhance patient access to innovative and high-quality healthcare solutions. Wang Li, president of SUP, said, "We are truly honored to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI. Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.05% to Rs 2,001.45 on the BSE.
&w=3840&q=100)
Business Standard
16-06-2025
- Business
- Business Standard
Lupin inks pact with China's Sino Universal for Tiotropium inhaler supply
Pharma major Lupin Ltd on Monday said it has signed a license and supply agreement with China's Sino Universal Pharmaceuticals for the commercialisation of Tiotropium dry powder inhaler in the Chinese market. The agreement pertains to the commercialisation of the Tiotropium dry powder inhaler of strength 18 mcg/capsule, which is used in the treatment of Chronic Obstructive Pulmonary Disease (COPD), Lupin said in a regulatory filing. Under the agreement, Sino Universal Pharmaceuticals (SUP) will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorisation holder and responsible for manufacturing of the product, it added. "This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector," Lupin President Corporate Development, Fabrice Egros said. With SUP, the company aim to enhance patient access to innovative and high-quality healthcare solutions, Egros added. Commenting on the partnership, SUP President Wang Li said, "Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care." By bringing more efficient and superior products to market, Li said, "We aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin said the partnership will enable it to expand its footprint in China. Tiotropium dry powder inhaler is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions, Lupin said. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
16-06-2025
- Business
- Time of India
Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Pharma major Lupin Ltd on Monday said it has signed a license and supply agreement with China's Sino Universal Pharmaceuticals for the commercialisation of Tiotropium dry powder inhaler in the Chinese agreement pertains to the commercialisation of the Tiotropium dry powder inhaler of strength 18 mcg/capsule, which is used in the treatment of Chronic Obstructive Pulmonary Disease (COPD), Lupin said in a regulatory the agreement, Sino Universal Pharmaceuticals (SUP) will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorisation holder and responsible for manufacturing of the product, it added."This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector," Lupin President Corporate Development, Fabrice Egros SUP, the company aim to enhance patient access to innovative and high-quality healthcare solutions , Egros on the partnership, SUP President Wang Li said, "Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care."By bringing more efficient and superior products to market, Li said, "We aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health."Lupin said the partnership will enable it to expand its footprint in dry powder inhaler is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions, Lupin said. PTI
